Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr329.10 DKK
Change Today +1.80 / 0.55%
Volume 100.5K
CHR On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
OTC US
Frankfurt
As of 11:07 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

chr hansen holding a/s (CHR) Snapshot

Open
kr327.40
Previous Close
kr327.30
Day High
kr330.00
Day Low
kr325.70
52 Week High
04/13/15 - kr362.00
52 Week Low
10/16/14 - kr202.50
Market Cap
43.4B
Average Volume 10 Days
232.3K
EPS TTM
kr1.08
Shares Outstanding
131.9M
EX-Date
11/28/14
P/E TM
40.9x
Dividend
kr3.77
Dividend Yield
1.15%
Current Stock Chart for CHR HANSEN HOLDING A/S (CHR)

Related News

No related news articles were found.

chr hansen holding a/s (CHR) Related Businessweek News

No Related Businessweek News Found

chr hansen holding a/s (CHR) Details

Chr. Hansen Holding A/S, a bioscience company, develops and sells natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. The company’s Cultures and Enzymes division produces and sells cultures, enzymes, and probiotic products that determine the taste, flavor, color, texture, safety, preservation, nutritional value, and health benefits of various consumer products in the food and dairy industries. Its Health and Nutrition division provides probiotic cultures for the dietary supplement, over-the-counter pharmaceutical, infant formula, and animal feed and plant protection industries. The company’s Natural Colors division offers natural color solutions for the food industries, primarily including the beverage, confectionery, ice cream, dairy, fruit preparation, and prepared food segments. It has strategic alliance with FMC Corporation for development and commercialization of biological plant protection products. The company operates in Europe, the Middle East, Africa, North and South America, and the Asia Pacific. Chr. Hansen Holding A/S was founded in 1874 and is headquartered in Hørsholm, Denmark.

2,500 Employees
Last Reported Date: 04/9/15
Founded in 1874

chr hansen holding a/s (CHR) Top Compensated Officers

Chief Executive Officer, President and Member...
Total Annual Compensation: €890.0K
Executive Vice President of Cultures & Enzyme...
Total Annual Compensation: €620.0K
Executive Vice President of Natural Colors Di...
Total Annual Compensation: €480.0K
Compensation as of Fiscal Year 2014.

chr hansen holding a/s (CHR) Key Developments

Chr. Hansen Holding A/S Announces Executive Changes

Chr. Hansen announced Carsten Bennike, Executive Vice President of the Natural Colors Division will leave the company as of 30 June, 2015. Jørgen M. Erichsen will take over the position on 1 July, 2015. Carsten Bennike has been with Chr. Hansen since March 2011. Jørgen M. Erichsen, comes from a position as Vice President Sales & Marketing, EMEA and member of the Global Executive Committee in Logitech International in Switzerland.

Chr. Hansen Holding Intends to Pay Interim Dividend

Chr. Hansen Holding announced its intention to pay an interim dividend of EUR 115 million.

Chr. Hansen Holding A/S Reports Unaudited Earnings Results for the Second Quarter and Year to Date Ended February 28, 2015; Provides Unchanged Earnings Guidance for the Year 2015

Chr. Hansen Holding A/S reported unaudited earnings results for the second quarter and year to date ended February 28, 2015. For the quarter, the company reported revenue of EUR 208.8 million compared to EUR 181.5 million a year ago. EBIT before special items was EUR 52.5 million compared to EUR 45.0 million a year ago. Profit for the period was EUR 35.5 million compared to EUR 27.1 million a year ago. Free cash flow was EUR 41.6 million compared to EUR 32.3 million a year ago. EBIT was EUR 52.5 million compared to EUR 41.6 million a year ago. Profit before tax was EUR 47.9 million compared to EUR 37.1 million a year ago. Profit attributable to shareholders of the company was EUR 35.5 million compared to EUR 27.1 million a year ago. Basic and diluted earnings per share from continuing operations was EUR 0.27 compared to EUR 0.20 a year ago. Cash flow from operating activities was EUR 55.1 million compared to EUR 45.1 million a year ago. Investments in intangible assets were EUR 3.7 million compared to EUR 2.6 million a year ago. Investments in property, plant and equipment was EUR 9.8 million compared to EUR 10.2 million a year ago. EBITDA before special items was EUR 66.1 million compared to EUR 57.9 million a year ago. For the year to date, the company reported revenue of EUR 396.9 million compared to EUR 352.8 million a year ago. EBIT before special items was EUR 96.0 million compared to EUR 88.1 million a year ago. Profit for the period was EUR 65.3 million compared to EUR 56.2 million a year ago. Free cash flow was EUR 11.2 million compared to EUR 1.2 million a year ago. EBIT was EUR 96.0 million compared to EUR 84.1 million a year ago. Profit before tax was EUR 88.2 million compared to EUR 77.1 million a year ago. Profit attributable to shareholders of the company was EUR 65.3 million compared to EUR 56.2 million a year ago. Basic and diluted earnings per share from continuing operations was EUR 0.50 compared to EUR 0.42 a year ago. Cash flow from operating activities was EUR 39.0 million compared to EUR 27.5 million a year ago. Investments in intangible assets were EUR 6.4 million compared to EUR 7.0 million a year ago. Investments in property, plant and equipment was EUR 21.4 million compared to EUR 19.3 million a year ago. EBITDA before special items was EUR 123.2 million compared to EUR 113.7 million a year ago. The outlook of the company for the year 2015 is unchanged compared to the announcements of October 22, 2014 and January 21, 2015, whereas outlook for the divisions has been further specified with regard to second half growth in the Health & Nutrition Division and currency impact on EBIT margin in the Health & Nutrition and Natural Colors divisions. Organic revenue growth is expected to be 7% to 9%. Research & development expenditures incurred are expected to be 7% to 8%. Free cash flow before acquisitions, divestments and special items is expected to be above EUR 130 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CHR:DC kr329.10 DKK +1.80

CHR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Balchem Corp $58.11 USD -0.90
Corbion NV €19.01 EUR -0.395
Ebro Foods SA €17.33 EUR +0.08
Sensient Technologies Corp $67.79 USD -0.52
Shanghai Jiaoda Onlly Co Ltd CNY28.82 CNY 0.00
View Industry Companies
 

Industry Analysis

CHR

Industry Average

Valuation CHR Industry Range
Price/Earnings 40.2x
Price/Sales 7.1x
Price/Book 8.7x
Price/Cash Flow 40.5x
TEV/Sales 6.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHR HANSEN HOLDING A/S, please visit www.chr-hansen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.